The regulator had issued alerts in June and July of 2015.
Alkem Labs was issued drug alerts twice last year -- in June and July -- for its drug Glimekem.
Alkem, the largest manufacturer of Fructo-Oligo Saccharides, which helps the growth of good probiotic bacteria, is planning to roll out more products in the national and global markets, said Sharad.
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
Indian companies have raised $1 billion so far this year - almost four times what they raised last year.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Nutraceuticals, consisting of dietary supplements and functional foods with curative or nutritional benefits, are estimated to have a sales of $190 billion globally by 2010. India's food supplement and health food market is estimated currently at about $400 million. The country already has a clutch of established players focussing in this segment such as Avesthagen, Himalaya and Sami Labs.
Indian companies are now more confident about the execution skills of local banks.
Financial shares were the top losers.
Unfavourable secondary market conditions aren't a big concern for IPOs by good quality companies.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
The government must not enter into what will be a little more than a large-scale transfer of taxpayers' money to the operators of private hospitals.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Metal shares were the top gainers with Hindalco up over 5%.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances